-
TREM2: Exploring Its Role in Tumor-Associated Macrophages and Cancer Immunotherapy(Post)
Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophages
microbiota & immune system signaling | Assay Genie(Post)You are only part human. In some ways, you are as much bacteria as you are mammal, and in some ways bacteria make up far more of you than your own familiar cells and genes! It is becoming
Agonist Antibodies: Why CD40, OX40 & 4-1BB Need FcγR Crosslinking(Page) Leukocytes : Basics to Diseases(Post)Only 1% of our blood is made up of white blood cells, but they have a significant impact. Alternatively referred to as leukocytes, white blood cells. We are shielded from disease and
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
The IL-36 Subfamily | Expression, Function & Regulation(Post)By Charlotte O'Donnell PhD The genes of the IL-36 family members are located in a cluster on chromosome 2 [1]. All three activating ligands, IL-36α, IL-36β a
Transformation Protocol – Sample Transformation Protocols(Post)Introduction Transformation of bacteria with plasmids is not only of note for bacterial studies but also can be used for gene expression studies in mammalian cells. Most plasmids are of bact
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Amino Acid and Protein Assays(Page) Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Acute Lymphoblastic Leukaemia Review | Assay Genie(Post)Incidence rate of Acute Lymphoblastic Leukaemia Acute lymphoblastic leukaemia (ALL) is one of the most common malignant diseases diagnosed in children. It
Biomarkers & Inflammatory markers of atherosclerosis(Post)As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related di
Immuno Oncology: If cancer was a pathogen, would a vaccine be able to destroy it?(Post)Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the
Targeting IL-10R: Enhancing Immune Activation in Cancer(Post)Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
What are MHC Class I and II molecules?(Post)What are MHC Class I molecules? The MHC class I is a glycoprotein that is expressed on all nucleated cells of the human body. MHC class I are important in disease defense against viruses, ba
What is the difference between PBS and dPBS?(Post)Lab Buffers · ProtocolsPBS vs DPBS: What’s the Difference?PBS and DPBS are the everyday isotonic, pH-balanced salt solutions used to wash, dilute and transport cells and proteins. This guide bre
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C
Ulocuplumab: Targeting CXCR4 in Cancer Research and Beyond(Post)Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell